To further explore this potential mechanism, recent studies have confirmed that Tregs compete for intratumoral IL-2, mediating IL-2/STAT5 signaling to inhibit the activation of tumor-infiltrating CD8+ T cells and induce exhaustion through the upregulation of thymocyte selection-associated high mobility group box protein (TOX) (27). The gene discussed is CD8A; the disease is neoplasm.